ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016 ACR/ARHP Annual Meeting
    • 2015 ACR/ARHP Annual Meeting
    • 2014 ACR/ARHP Annual Meeting
    • 2013 ACR/ARHP Annual Meeting
    • 2012 ACR/ARHP Annual Meeting
    • 2011 ACR/ARHP Annual Meeting
    • 2010 ACR/ARHP Annual Meeting
    • 2009 ACR/ARHP Annual Meeting
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Adalimumab and juvenile arthritis"

  • Abstract Number: 764 • 2012 ACR/ARHP Annual Meeting

    The Impact of Adalimumab On Growth in Patients with Juvenile Idiopathic Arthritis

    D. J. Lovell1, Nicolino Ruperto2, Katerina Jarosova3, Dana Nemcova4, Veronika Vargova3, Hartmut Michels3, Elizabeth Chalom5, Norman Ilowite5, Carine Wouters6, Hermine Brunner7, Karolyn Kracht8, Hartmut Kupper9, Edward Giannini5, Alberto Martini10 and Neelufar Mozaffarian11, 1Cincinnati Children's Hospital, Cincinnati, OH, 2Paediatric Rheumatology International Trials Organisation–IRCCS [PRINTO], Genova, Italy, 3PRINTO, Gaslini Institute, Genova, Italy, 4Pediatric Rheumatology Unit, Department of Pediatrics and Adolescent Medicine, General University Hospital in Prague, Prague, Czech Republic, 5PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, 6PRINTO, Genoa, Italy, 7PRCSG, Cincinnati Children’s Hospital Medical Center, Genova, Italy, 8Abbott, Abbott, Abbott Park, IL, 9Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany, 10Pediatric Rheumatology Collaborative Study Group [PRSCG], Cincinnati, OH, 11Abbott, Abbott Park, IL

     Background/Purpose: Children with juvenile idiopathic arthritis (JIA) often exhibit growth impairments. Treatment with adalimumab (ADA) has been shown to be safe and effective in JIA…
  • Abstract Number: 1148 • 2012 ACR/ARHP Annual Meeting

    Adalimumab – Effective Control under Refractory JIA Associated Uveitis

    Ekaterina Alekseeva1, Elena Mitenko2, Tatyana Bzarova2, Saniya Valieva2, Kseniya Isayeva2, Alexandra Chomakhidze2, Evgeniya Chistyakova2, Tatyana Sleptsova2 and Rina Denisova2, 1PRINTO, Genoa, Italy, 2Rheumatology, Scientific Center of Children's Health, Moscow, Russia

    Background/Purpose: Treatment of juvenile idiopathic arthritis (JIA)–associated uveitis  is one of the serious problems of paediatric rheumatology. JIA associated uveitis often is refractory to MTX,…
  • Abstract Number: 1678 • 2012 ACR/ARHP Annual Meeting

    Safety and Efficacy of Adalimumab in Children with Active Polyarticular Juvenile Idiopathic Arthritis Aged 2 to <4 Years or ≥4 Years Weighing <15 Kg

    Daniel J. Kingsbury1, Pierre Quartier2, Gina Patel3, Vipin Arora4, Hartmut Kupper5 and Neelufar Mozaffarian3, 1Randall Children's Hospital at Legacy Emanuel, Portland, OR, 2Unite d'Immuno-Hematologie et Rhumatologie Pediatriques, Paris, France, 3Abbott, Abbott Park, IL, 4Health Outcomes Research, Abbott, Abbott Park, IL, 5Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany

    Background/Purpose: Adalimumab (ADA) is approved for use in moderate to severe JIA in patients (pts) ≥4 yrs old in the US, EU,and Japan. ADA has…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Annual Meeting in Atlanta, Georgia

© COPYRIGHT 2019 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.